Green tea (Camellia sinensis) Attenuates Nephropathy by Downregulating Nox4 NADPH Oxidase in Diabetic Spontaneously Hypertensive Rats

Pérola D. B. Ribaldo, Denise S. Souza, Subrata K. Biswas, Karen Block, Jacqueline M. Lopes de Faria, and José B. Lopes de Faria

Abstract

Green tea (GT), through its antioxidant properties, may be useful to treat or prevent human diseases. Because several lines of evidence suggest that oxidative stress contributes to the pathogenesis of diabetic nephropathy, we tested the hypothesis that GT prevents diabetes and hypertension-related renal oxidative stress, attenuating renal injury. Spontaneously hypertensive rats (SHR) with streptozotocin-induced diabetes and nondiabetic SHR were treated daily with tap water or freshly prepared GT (13.3 g/L). After 12 wk, the systolic blood pressure did not differ between treated and untreated nondiabetic or diabetic rats. However, body weight was less (P < 0.05) and glycemia was greater in diabetic SHR rats than in nondiabetic rats. Renal oxidative stress variables such as 8-hydroxy-2'-deoxyguanosine (8-OHdG) and nitrotyrosine expression, NADPH oxidase-dependent superoxide generation, and the expression of renal cortex Nox4 were greater (P < 0.05) in diabetic rats that received water (DW) than in nondiabetic rats that received water (CW). The 8-OHdG and NADPH oxidase-dependent superoxide generation were significantly less in rats treated with GT. Nitrotyrosine and Nox4 expression were significantly less in diabetic rats that received GT (DGT) than in DW. Likewise, the indices of renal injury, albuminuria, and renal expression of collagen IV were significantly greater in DW than in CW. These differences were significantly less in DGT than in DW. GT reestablished the redox state and reduced the indicators of nephropathy without altering glycemia and blood pressure levels in diabetic SHR. These findings suggest that the consumption of GT may ameliorate nephropathy in diabetic hypertensive patients. J. Nutr. 139: 96–100, 2009.

Introduction

Hypertension and diabetes frequently coexist, and the presence of these 2 conditions significantly magnifies the risk of nephropathy (1). Accordingly, blood glucose and blood pressure are among the most effective maneuvers for the treatment and prevention of diabetic renal disease (2–5). Likewise, the presence of hypertension in experimental diabetes mellitus (DM) aggravates and anticipates renal abnormalities (6) that can be prevented by antihypertensive therapy (7).

Diabetic nephropathy is primarily metabolic and hemodynamic in origin and results from interaction between genetic susceptibility and environmental factors (8). There is considerable evidence that oxidative stress has a role in the pathogenesis of diabetic nephropathy (9). Hyperglycemia and hypertension can activate multiple pathways that lead to increased generation of superoxide anions and other reactive oxygen species (ROS) (reviewed in 10, 11). Some of these pathways include enhanced activity of the mitochondrial electron transport chain induced by hyperglycemia (12), increased expression, and uncoupling of endothelial nitric oxide synthase, leading to greater production of superoxide relative to nitric oxide (9) and activation of the reduced forms of NADPH (13–15). The latter system is present in different renal cell types (16, 17) and may contribute to renal damage in the presence of diabetes or hypertension (18, 19). In addition, we have recently shown that hypertension increases renal oxidative stress by elevating NADPH-dependent superoxide production and decreasing antioxidant defenses in spontaneously hypertensive rats (SHR) with streptozotocin (STZ)-induced diabetes (19).
Strategies that reduce superoxide formation via NADPH oxidase and/or increase the activity of antioxidant defense systems can attenuate hyperglycemia-induced renal injury (18,20–22). For instance, phosphorothioated antisense oligonucleotides for Nox4, a homolog of the gp91phox subunit of NADPH oxidase, inhibits NADPH-dependent ROS generation in the renal cortex and reduces glomerular hypertrophy and the expression of renal fibronectin (20).

Green tea (GT; *Camellia sinensis*) is a rich source of polyphenols, particularly flavonoids that have beneficial effects in the treatment of certain forms of cancer, arthritis, and cardiovascular disorders (reviewed in 23). The administration of epigallocatechin gallate, a polyphenol that accounts for ∼30% of the dry weight of GT, to SHR improves endothelial function and insulin sensitivity and reduces blood pressure (24). In rats with STZ-induced diabetes, the administration of GT in the drinking water improves renal function and reduces the blood glucose and glycated protein concentrations (25). GT also attenuates the retinopathy and renal mitochondrial ROS production in this same model (27). Although most of the biological actions of GT have been attributed to its antioxidant properties (23), there has been no systematic study of its efficacy in preventing oxidative stress caused by hypertension and hyperglycemia, thereby protecting against renal injury.

In this work, we tested the hypothesis that GT attenuates renal injury in diabetic hypertensive rats. In addition, to explore the underlying molecular mechanisms, we examined the effects of GT on the expression of NADPH oxidase Nox4, which is a major source of ROS production in the kidney (20).

**Materials and Methods**

*Rats and experimental protocol.* This study complied with the guidelines of the Brazilian College for Animal Experimentation and was approved by the institutional Committee for Ethics in Animal Experimentation (CEEA/IB/UNICAMP, protocol no. 1119–1). SHR (Taconic) bred in our animal facility were used in this study. Experimental diabetes was induced in 12-wk-old hypertensive male SHR (∼250 g) by a single i.v. (tail vein) injection of STZ (50 mg/kg; dissolved in sodium citrate buffer, pH 4.5; Sigma) after overnight food deprivation. Nondiabetic SHR received only vehicle (citrate buffer). Seventy-two hours after the injection of STZ or citrate buffer, blood glucose concentrations were measured with a colorimetric enzymatic GOD-PAP assay (Merck) in rats deprived of food for 4 h. Rats with blood glucose concentrations ≥15 mmol/L were considered diabetic for these experiments. Diabetic and nondiabetic SHR were randomly assigned to groups of 8 rats each that received only water [nondiabetic water (CW; n = 8) and diabetic water (DW; n = 8)] or GT [nondiabetic GT (CGT; n = 8) and diabetic GT (DGT; n = 8)] as their sole source of drinking water for 12 wk. All of the rats were housed in groups of 4 and were fed nonpurified, pelleted rat diet containing 22% protein, 55% carbohydrate, and 4.5% fat (Nuvital Nutrientes S/A). Diabetic rats received 2 U of long-acting insulin (Novo Industry A/S) 3 times each week. Japanese GT (Midori Indústria de Chá) was prepared daily as described by the manufacturer: 10 g of dry tea was added to 750 mL of deionized boiled tap water cooled to 90°C and then brewed for 3 min, decanted, filtered, placed on ice, and protected from light with aluminum foil.

**Variables measured.** Body weight, plasma glucose, systolic blood pressure (SBP), and albumin excretion rate (AER) were measured at 0, 4, 8, and 12 wk. The rats were killed by CO2 asphyxia 12 wk after the induction of diabetes. The abdomen was opened via a midline incision and the right kidney was immediately removed, decapsulated, weighed, and processed for homogenization of the cortical tissue. The left kidney was similarly removed and cut longitudinally into 2 halves; one half was frozen in liquid nitrogen and stored at −80°C and the other half was fixed by immersion in methacarn (60% methanol, 30% chloroform, and 10% glacial acetic acid).

**SBP measurements.** SBP was measured by tail-cuff plethysmography with an MK III physiograph (Narco Bio-System) in unanesthetized rats before randomization (5 determinations per rat) and every 4 wk throughout the experiment.

**TABLE 1**  
Physiological variables measured monthly from nondiabetic and diabetic SHR that consumed water or GT for 12 wk.

<table>
<thead>
<tr>
<th>Variable</th>
<th>0</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>Effect²</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body weight, g</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CW</td>
<td>256 ± 20.4</td>
<td>338.6 ± 44.3</td>
<td>350.8 ± 33.5</td>
<td>354.3 ± 37.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGT</td>
<td>259.9 ± 16.1</td>
<td>315.9 ± 16.4</td>
<td>333.9 ± 18.3</td>
<td>349.3 ± 21.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DW</td>
<td>256.4 ± 23.6</td>
<td>210.2 ± 47.4</td>
<td>229.6 ± 30.8</td>
<td>252.3 ± 24.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DGT</td>
<td>201.5 ± 23.7</td>
<td>249 ± 25.5</td>
<td>242.9 ± 56.8</td>
<td>277.5 ± 52.2</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>SBP, mm Hg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.038</td>
<td></td>
</tr>
<tr>
<td>CW</td>
<td>188.2 ± 15.4</td>
<td>196.7 ± 13.9</td>
<td>203.2 ± 13.8</td>
<td>202.2 ± 13.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGT</td>
<td>178.2 ± 11.3</td>
<td>185.9 ± 12.4</td>
<td>186.9 ± 14.5</td>
<td>197.9 ± 7.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DW</td>
<td>178.4 ± 11.1</td>
<td>180.7 ± 9.4</td>
<td>192.5 ± 16.4</td>
<td>192.1 ± 16.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DGT</td>
<td>186.3 ± 13.3</td>
<td>188.6 ± 17.5</td>
<td>188.9 ± 22.3</td>
<td>193.2 ± 16.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood glucose, mmol/L</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>CW</td>
<td>8.8 ± 1.0</td>
<td>10.4 ± 3.0</td>
<td>8.2 ± 2.0</td>
<td>8.6 ± 1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGT</td>
<td>8.8 ± 0.6</td>
<td>9.6 ± 2.5</td>
<td>8.7 ± 1.7</td>
<td>8.9 ± 1.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DW</td>
<td>25.1 ± 3.0</td>
<td>26.4 ± 3.6</td>
<td>34.8 ± 4.8</td>
<td>25.8 ± 3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DGT</td>
<td>24.1 ± 4.1</td>
<td>27.9 ± 6.5</td>
<td>32.3 ± 8.7</td>
<td>27.0 ± 4.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urine volume, mL/24 h</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>CW</td>
<td>25.8 ± 12.1</td>
<td>32.0 ± 8.8</td>
<td>40.9 ± 6.5</td>
<td>37.3 ± 22.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGT</td>
<td>23.0 ± 1.4</td>
<td>36.4 ± 14.5</td>
<td>34.8 ± 9.9</td>
<td>30.3 ± 7.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DW</td>
<td>24.1 ± 7.4</td>
<td>75.4 ± 15.0</td>
<td>86.6 ± 19.0</td>
<td>65.6 ± 25.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DGT</td>
<td>22.4 ± 8.6</td>
<td>86.3 ± 13.4</td>
<td>83.4 ± 18.0</td>
<td>69.6 ± 35.2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Values are expressed as means ± SD, n = 8.

2. Significant effects detected in repeated-measures 2-way ANOVA.
Results

Physiological variables. Body weight gain was less (P < 0.0001) in diabetic SHR than in control rats. The relative kidney weight was markedly greater (P < 0.0001) in DW (0.52 ± 1.0 g/100 g body) than in both CW (3.8 ± 0.3) and CGT (3.7 ± 0.2). The SBP was similar in all groups. The blood glucose concentration was greater in diabetic rats than in controls but was not affected by GT (Table 1).

NADPH-dependent superoxide generation, Nox4 expression, and oxidative stress markers. NADPH-dependent superoxide production was greater (P = 0.01) in renal cortical homogenates of DW rats compared with the control rats and was less (P = 0.01) in GT-treated groups (Fig. 1). Preincubation of renal cortical homogenates with diphenyleneiodonium (final concentration, 20 μmol/L) completely blocked NADPH-induced superoxide production, whereas preincubation with rotenone (final concentrations of 20 and 100 μmol/L) did not affect superoxide production (data not shown). These results indicated that NADPH oxidase was the most likely source of superoxide anion.

The expression of Nox4 was greater (P = 0.04) in the DW group than in the CW group and it was reduced to the levels of both control groups in the DGT (DW x GT, P = 0.03) (Fig. 2A,B).

Renal injury indices. The urinary AER and the accumulation of kidney collagen IV were used as markers of functional and morphological renal injury, respectively. The AER estimated as the AUC was greater (P = 0.048) in the DW group than in the CW group and was less in the DGT group than in the DW group (Fig. 3). Western blotting showed that renal cortical expression of collagen IV was greater (P = 0.01) in DW rats than in nondiabetic SHR and was reduced to the levels of both nondiabetic groups in the DGT (DM x GT, P = 0.03) (Fig. 4A,B).
The results of this study show that GT ameliorates the albuminuria and renal accumulation of collagen IV and reduces markers of renal oxidative stress in diabetic SHR. The underlying mechanism of these beneficial effects apparently involves the downregulation of NADPH oxidase Nox4 expression.

The adequate control of blood pressure and blood glucose concentration is central to the treatment and prevention of renal lesions in diabetes (2–5). GT and epigallocatechin gallate, the main polyphenolic component of GT, reduce blood glucose in diabetic rats (25,29), although this effect is not always observed (26). Our findings agree with the latter study, because GT did not affect the blood pressure or blood glucose concentrations of SHR. This observation further supports the importance of oxidative stress in the renal injury seen here and strengthens the supposition that the beneficial effects of GT in renal tissue were mediated by restoration of the redox status.

Nox4, a homolog of the gp91phox subunit of NADPH, is highly expressed in the kidney (20,30). Overexpression of Nox4 in the kidney of diabetic rats with STZ-induced diabetes may play an important role in increased ROS production (20,31). Gorin et al. (20) reported that downregulation of Nox4 induced by antisense oligonucleotides completely attenuated oxidative stress in the kidneys of rats with STZ-induced diabetes and that there was a concomitant reduction in glomerular hypertrophy and the accumulation of fibronectin. Similarly, Fujii et al. (32) found that the administration of a statin, pitavastatin, to db/db mice ameliorated the albuminuria and renal mesangial expansion by downregulating Nox4. In agreement with these findings, the downregulation of Nox4 by GT completely attenuated oxidative stress and renal injury in diabetic SHR. The molecular mechanism by which GT regulates Nox4 activity remains to be elucidated.

In conclusion, GT ameliorates renal injury in diabetic hypertensive rats by inhibiting oxidative stress through downregulation of Nox4 expression. These findings suggest that GT consumption may be beneficial in diabetic hypertensive patients.

**Acknowledgments**

We thank Sergio Magalhães for technical assistance and Kamila C. Silva, Renata Serrer, Elisa B. M. Peixoto, Bruno S. Pessoa, Camila C. Pinto, Mariana Rosales, Christine Marinho, Felipe Val, and
Adriana Matos for help with various laboratory procedures. We also thank Stephen Hyslop for editing the manuscript.

**Literature Cited**


